Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario
Background: Dedifferentiated liposarcoma (DDLPS) is a rare, aggressive tumour with poor survival outcomes in advanced settings. This study assessed the incidence/prevalence, treatment patterns, survival, healthcare resource utilization (HCRU), and costs for DDLPS patients in Ontario, Canada. Methods...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/5/273 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850257623971004416 |
|---|---|
| author | Soo Jin Seung Anisia Wong Raymond Milan Nisha Chandran Albiruni R. Abdul Razak |
| author_facet | Soo Jin Seung Anisia Wong Raymond Milan Nisha Chandran Albiruni R. Abdul Razak |
| author_sort | Soo Jin Seung |
| collection | DOAJ |
| description | Background: Dedifferentiated liposarcoma (DDLPS) is a rare, aggressive tumour with poor survival outcomes in advanced settings. This study assessed the incidence/prevalence, treatment patterns, survival, healthcare resource utilization (HCRU), and costs for DDLPS patients in Ontario, Canada. Methods: A retrospective cohort study was conducted among DDLPS patients between 2010 and 2022 using administrative databases. Overall survival, all-cause HCRU, and costs (2023 Canadian dollars, CAD) were compared based on advanced disease and resection status. Results: The overall incidence and cumulative prevalence of DDLPS was 0.465 and 1.995 per 100,000 people, respectively. Of all 611 DDLPS cases (64.3% male, median age [IQR]: 67 [57–76] years), 40.3% and 61.0% had advanced and unresected disease, respectively. The median overall survival (mOS) was 69 months [IQR = 15–151] for the entire cohort, but this was significantly lower for advanced and unresected disease (<i>p</i> < 0.0001). Among patients receiving systemic treatments (N = 117), 81.2% were prescribed doxorubicin as first-line treatment. All-cause healthcare costs (2023 CAD) amounted to CAD 34,448 per person-year (PPY), with inpatient hospitalizations being the highest cost driver at CAD 14,522 PPY and 0.8 inpatient hospitalization PPY for all years. Advanced disease had higher HCRU and costs. Conclusions: This is the first comprehensive real-world evidence study that quantifies the high mortality and cost burden associated with DDLPS in Canada. |
| format | Article |
| id | doaj-art-f92d451a17934350a7317ccb05c31ebd |
| institution | OA Journals |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-f92d451a17934350a7317ccb05c31ebd2025-08-20T01:56:23ZengMDPI AGCurrent Oncology1198-00521718-77292025-05-0132527310.3390/curroncol32050273Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in OntarioSoo Jin Seung0Anisia Wong1Raymond Milan2Nisha Chandran3Albiruni R. Abdul Razak4HOPE Research Centre, Sunnybrook Research Institute, Toronto, ON M4N 3M5, CanadaHOPE Research Centre, Sunnybrook Research Institute, Toronto, ON M4N 3M5, CanadaBoehringer Ingelheim Canada Ltd., Burlington, ON L7L 5H4, CanadaBoehringer Ingelheim Canada Ltd., Burlington, ON L7L 5H4, CanadaToronto Sarcoma Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, CanadaBackground: Dedifferentiated liposarcoma (DDLPS) is a rare, aggressive tumour with poor survival outcomes in advanced settings. This study assessed the incidence/prevalence, treatment patterns, survival, healthcare resource utilization (HCRU), and costs for DDLPS patients in Ontario, Canada. Methods: A retrospective cohort study was conducted among DDLPS patients between 2010 and 2022 using administrative databases. Overall survival, all-cause HCRU, and costs (2023 Canadian dollars, CAD) were compared based on advanced disease and resection status. Results: The overall incidence and cumulative prevalence of DDLPS was 0.465 and 1.995 per 100,000 people, respectively. Of all 611 DDLPS cases (64.3% male, median age [IQR]: 67 [57–76] years), 40.3% and 61.0% had advanced and unresected disease, respectively. The median overall survival (mOS) was 69 months [IQR = 15–151] for the entire cohort, but this was significantly lower for advanced and unresected disease (<i>p</i> < 0.0001). Among patients receiving systemic treatments (N = 117), 81.2% were prescribed doxorubicin as first-line treatment. All-cause healthcare costs (2023 CAD) amounted to CAD 34,448 per person-year (PPY), with inpatient hospitalizations being the highest cost driver at CAD 14,522 PPY and 0.8 inpatient hospitalization PPY for all years. Advanced disease had higher HCRU and costs. Conclusions: This is the first comprehensive real-world evidence study that quantifies the high mortality and cost burden associated with DDLPS in Canada.https://www.mdpi.com/1718-7729/32/5/273dedifferentiated liposarcomatreatment patternssurvivalhealthcare resource utilizationcosts |
| spellingShingle | Soo Jin Seung Anisia Wong Raymond Milan Nisha Chandran Albiruni R. Abdul Razak Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario Current Oncology dedifferentiated liposarcoma treatment patterns survival healthcare resource utilization costs |
| title | Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario |
| title_full | Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario |
| title_fullStr | Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario |
| title_full_unstemmed | Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario |
| title_short | Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario |
| title_sort | epidemiology treatment patterns survival healthcare resource utilization and costs of dedifferentiated liposarcoma ddlps in canada a retrospective cohort study using administrative databases in ontario |
| topic | dedifferentiated liposarcoma treatment patterns survival healthcare resource utilization costs |
| url | https://www.mdpi.com/1718-7729/32/5/273 |
| work_keys_str_mv | AT soojinseung epidemiologytreatmentpatternssurvivalhealthcareresourceutilizationandcostsofdedifferentiatedliposarcomaddlpsincanadaaretrospectivecohortstudyusingadministrativedatabasesinontario AT anisiawong epidemiologytreatmentpatternssurvivalhealthcareresourceutilizationandcostsofdedifferentiatedliposarcomaddlpsincanadaaretrospectivecohortstudyusingadministrativedatabasesinontario AT raymondmilan epidemiologytreatmentpatternssurvivalhealthcareresourceutilizationandcostsofdedifferentiatedliposarcomaddlpsincanadaaretrospectivecohortstudyusingadministrativedatabasesinontario AT nishachandran epidemiologytreatmentpatternssurvivalhealthcareresourceutilizationandcostsofdedifferentiatedliposarcomaddlpsincanadaaretrospectivecohortstudyusingadministrativedatabasesinontario AT albirunirabdulrazak epidemiologytreatmentpatternssurvivalhealthcareresourceutilizationandcostsofdedifferentiatedliposarcomaddlpsincanadaaretrospectivecohortstudyusingadministrativedatabasesinontario |